Prime Medicine (PRME) Equity Ratio (2021 - 2025)
Historic Equity Ratio for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to 0.42.
- Prime Medicine's Equity Ratio fell 2619.18% to 0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42, marking a year-over-year decrease of 2619.18%. This contributed to the annual value of 0.51 for FY2024, which is 2501.06% down from last year.
- According to the latest figures from Q3 2025, Prime Medicine's Equity Ratio is 0.42, which was down 2619.18% from 0.22 recorded in Q2 2025.
- Prime Medicine's Equity Ratio's 5-year high stood at 0.88 during Q1 2023, with a 5-year trough of 1.04 in Q3 2022.
- In the last 5 years, Prime Medicine's Equity Ratio had a median value of 0.63 in 2023 and averaged 0.44.
- Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 26958.38% in 2022, then plummeted by 7118.39% in 2025.
- Prime Medicine's Equity Ratio (Quarter) stood at 0.52 in 2021, then soared by 269.58% to 0.88 in 2022, then fell by 21.79% to 0.69 in 2023, then fell by 25.01% to 0.51 in 2024, then fell by 18.35% to 0.42 in 2025.
- Its Equity Ratio was 0.42 in Q3 2025, compared to 0.22 in Q2 2025 and 0.33 in Q1 2025.